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DObjectives: This study evaluated the safety and efficiency of the NeoChord DS1000 system (NeoChord, Inc,
Minneapolis, Minn), a device designed to deliver artificial chordae tendineae (neochords) in a beating heart
with minimally invasive techniques through left anterolateral minithoracotomy.
Methods: Thirteen patients with severe mitral regurgitation and isolated posterior mitral valve leaflet prolapsed
underwent operation with the NeoChord DS1000 system. Mitral valve dimensions were anteroposterior 34 mm
(29-45 mm) and mediolateral 40 mm (29-58 mm). All patients had an ejection fraction greater than 55%. With a
beating heart, through a left anterolateral thoracotomy, under transesophageal echocardiographic guidance,
the NeoChord DS1000 was introduced into the left ventricle 2 to 4 cm posterolateral from the apex. The
prolapsed leaflet was grasped with the device, and expanded polytetrafluoroethylene suture deployed and
attached to the posterior leaflet. Six patients received 2 sutures, 4 received 3 sutures, and 2 received 4 sutures.
All patients reached 6 months’ follow-up and underwent transthoracic echocardiography to evaluate mitral
regurgitation.
Results: Median operative duration was 113 minutes (80-150 minutes). Less than second-degree mitral regur-
gitation in 6 months was achieved in 11 patients (85%). One patient (8%) had recurrent mitral regurgitation in 1
month, and another had conversion to conventional mitral valve repair because of leaflet damagewith the device.
There were no further serious procedure-related complications.
Conclusions: Beating-heart transapical neochord implantation was feasible, could be performed safely, and re-
sulted in a relatively short procedure time. Larger studies and longer follow-up are needed to validate these
promising results. (J Thorac Cardiovasc Surg 2014;147:95-9)Techniques for mitral valve repair have undergone
continual evolution during the past 50 years.1 Simple poste-
rior leaflet prolapse is associated with very high mitral
repair rates in many centers.2,3 The overall repair rate of
69% observed in the Society of Thoracic Surgeons
database4 represents a progressive increase through an
8-year period but remains significantly lower than is achiev-
able. Acute mitral repair rates are now approximating 98%
for all common mitral disease etiologies in referral centers,1
even when applied to all comers.5 The lower overall Society
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The Journal of Thoracic and Cmore complex scenarios (including anterior or bileaflet
involvement, lesion complexity, and patient comorbidities)
and less experience on the part of many surgeons relative to
those at reference centers.5
Cumulative evidence obtained worldwide shows that
early surgery should be the preferred management
approach.6 Specifically, mitral repair should be performedFIGURE 1. NeoChord device. A, The NeoChord DS1000 consists of the
hand-held delivery instrument and a tethered Leaflet Verification Display.
B, As the device apex grasps the leaflet, the Leaflet Verification Display
gives information on leaflet grasping quality. C, The device deploys a su-
ture 4 mm from the leading edge of the target leaflet.
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Abbreviations and Acronyms
LV ¼ left ventricle
MR ¼ mitral regurgitation
TACT ¼ Transapical Artificial Chordae Tendineae
[trial]
TEE ¼ transesophageal echocardiography
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Dbefore New York Heart Association functional class III to
IV symptoms develop.7,8 NeoChord (NeoChord, Inc,
Minneapolis, Minn) has developed a new surgical tool for
less invasive off-pump, beating-heart mitral valve repair.
The NeoChord DS1000 system (Figure 1) is designed to
deliver artificial chordae tendineae, or neochords, under
beating-heart conditions with transesophageal echocardiog-
raphy used (TEE) to guide the device to the target leaflet for
deployment of the neochords. The multicenter, nonrandom-
ized, prospective Transapical Artificial Chordae Tendineae
(TACT) trial (clinicaltrials.gov ID: NCT01777815) for
evaluation of the NeoChord DS1000 system safety and
feasibility is ongoing. In this article, we report our first
experience with this device.MATERIALS AND METHODS
Patient Selection
The local bioethics committee has approved this prospective study, and
every patient provided individual consented to undergo the procedure.
From December 2011 to August 2012, 13 patients (5 male and 8 female)
underwent mitral valve repair with the DS1000 system at Vilnius Univer-
sity Hospital Santariskiu Klinikos, Vilnius, Lithuania. Median patientTABLE 1. Baseline characteristics, intraoperative data, and postoperative
Patient Age (y) Sex
Height
(cm)
Weight
(kg) NYHA L
1 65 F 162 75 II
2 61 M 176 92 II
3 69 F 156 60 III
4 73 F 155 65 II
5 63 M 178 93 II
6 49 M 186 97 II
7 38 M 185 87 II
8 62 F 170 98 II
9 72 F 167 75 III
10 62 F 167 80 III
11 69 F 170 65 III
12 68 M 183 90 III
13 33 F 172 58 II
Mean  SD 60  13 171  10 80  14
Range 33-73 155-186 58-98
MV, Mitral valve; NYHA, New York Heart Association functional class; LVEF, Left ventricu
LVESD, left ventricular end-systolic diameter; LVEDD, left ventricular end-diastolic diam
96 The Journal of Thoracic and Cardiovascular Surgeage was 60 years, with a range from 33 to 73 years. Median body mass in-
dex was 27 kg/m2, with a range from 20 to 34 kg/m2. All patients had good
function of the left ventricle (LV), with an ejection fraction greater than
55%. Per the protocol, all patients had severe mitral regurgitation (MR,
grade 3 or 4) with isolated posterior leaflet prolapse. All patients were can-
didates for conventional mitral valve surgery. Most patients had symptoms
of severe MR contributing to early-stage progression of heart failure, and
all patients were under medical treatment. Patients with functional or
ischemic MR, severe LV dysfunction, anterior or bileaflet prolapse, or per-
manent atrial fibrillation were excluded from this study. Baseline patient
characteristics are presented in Table 1. These patients were at low surgical
risk with an average euroSCORE II of 1.06% (0.56%-1.59%). With our
preoperative TEE assessment, we targeted patients exhibiting wide pro-
lapsing segments and patients in which clinically significant coaptation
depth (6-12 mm) could be restored.
Patient Screening
All patients underwent preoperative transthoracic echocardioscopy, and
most of the patients had 3-dimensional TEE to determine suitability for
transapical neochord implantation. Preoperative baseline echocardiograms
were used to determine the optimal planned number of neochords to be de-
ployed and their target location on the posterior leaflet. In general, deploy-
ment of more than 2 neochords is desired for each patient to balance the
load per neochord. Preoperative examination of the width of the prolapsing
segment or location of clefts in the leaflet tissue guided the target sites for
the planned neochords.
DS1000 Device
As shown in Figure 1, The NeoChord DS1000 consists of the handheld
delivery instrument and a tethered Leaflet Verification Display with 4 fiber-
optic lumens enabling confirmation of leaflet capture. Through a limited
left lateral thoracotomy in a beating heart, the device transapically accesses
the mitral valve, grasps the flailing leaflet, and deploys a suture as an arti-
ficial chord (4 mm from the leading edge of the target leaflet). Fiber optics
gives information of leaflet-grasping quality. If a leaflet is grasped with the
full depth of the device jaws, the Leaflet Verification Display will show 4results
Baseline
VEF (%)
MV annulus
distance (mm) MV leaflet (mm)
MR
gradeAP ML Anterior Posterior
55 26 33 15 13 3
55 32 44 21 17 3
55 32 33 21 18 3
55 30 37 20 11 3
55 30 29 17 14 3
55 35 28 20 11 3
55 45 57 27 22 3
55 3
55 29 35 17 20 3
55 35 53 24 21 3
55 34 39 17 28 4
55 33 41 21 23 4
55 30 40 22 17 4
33  5 39  8.9 20  3 18  5
26-45 28-57 15-27 11-28
lar ejection fraction; AP, anteroposterior;ML, mediolateral;MR, mitral regurgitation;
eter; LA, left atrial; F, female; M, male.
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FIGURE 2. Reverse remodeling at 6 months’ follow-up. A, Average left ventricular end-diastolic diameter (LVEDD) has reduced from 57.6 to 53.2 mm
(P¼ .002). B, Average left ventricular end-systolic diameter (LVESD) has increased nonsignificantly, from 35.2 to 35.5 mm (P¼ .86). C, Average indexed
left atrial (LA) volume has reduced from 69 to 55 mL/m2 (P ¼ .0004). Pt, Patient; Preop, preoperative.
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Dwhite lights; if the leaflet is grasped only partially, there will be just 1, 2, or
3 white lights. The suture is deployed only if the leaflet is grasped with full
depth of the jaws. The diameter of the instrument entering the LV is 8 mm
(24F).A
CNeoChord Procedure
The neochord implantation procedure was performed with the patient
under general anesthesia in ordinary cardiac surgery operating room.
TEE was used for guidance. Intraoperative blood salvage was used in all
cases. Access to the LV was achieved through a left lateral thoracotomy
in the fifth intercostal space (4-5 cm incision). Two standard purse-string
sutures were placed 2 to 4 cm posterolateral from the apex. A safe LV
access site was obtained by probing the LV with a blunt probe or finger
and viewing the proximity of the potential site to the papillary muscle.
After ventriculotomy, a NeoChord DS1000 device loaded with single
CV-4 suture (Gore-Tex; W. L. Gore & Associates, Inc, Flagstaff, Ariz)
was inserted in the LV, and 2- and 3-dimensional TEE used to navigate
the instrument to the flailing segment of the posterior mitral valve leaflet.Baseline Operative
LVESD
(mm)
LVEDD
(mm)
LA volume
index (mL/m2)
Operative
duration (min)
Intraoperative
MR post
procedure At
35 61 82
34 61 69 90 0
28 49 51 105 Trivial
30 54 63 100 Trivial
39 58 86 120 0
37 62 47 105 Trivial
38 61 80 115 Trivial
38 61 82 150 1
32 54 70 105 Trivial
33 58 68 80 Trivial
36 52 82 125 Trivial
50 66 67 120 Trivial
28 52 52 145 1
35  6 58  5 69  13 113  21 3.
28-50 52-66 47-86 80-150
TABLE 1. Continued
The Journal of Thoracic and CAlthough advancement of the distal tip could be impeded by the native
chordae, this was resolved with simple retraction of the device. Contact
with the native chordae was minimized by slowly advancing the device
while frequently observing the trajectory of the device in the long- and
short-axis views.
The jaws of the device were opened, and the flailing segment was
captured. Effective leaflet capture was confirmed by the 4 fiber-optic
monitor lights changing from red to white. Once a neochord was deployed,
the device was removed from the heart. Optimal placement of each
neochord was evaluated by placing the neochord under tension and
observing significant contribution to MR reduction. If the placement was
deemed inappropriate, a retrieval suture was used to remove the deployed
suture. The column for neochords attempted in Table 1 shows how many
attempts were made to implant neochords in each patient. Neochord
retrieval was accomplished by placing a polypropylene (Prolene; Ethicon,
Inc, Somerville, NJ) suture through the loop of the neochord. As the hitch
was advanced into position on the leaflet, the Prolene suture was advanced
with the hitch. Retrieval was completed by holding both free ends of
the Prolene suture while retracting the Prolene suture and expandedFollow up (6 mo)
Neochords
MR grade
LVESD
(mm)
LVEDD
(mm)
LA
measurements
(mm)tempted Left
Converted to standard care
3 2 1 45 60 64
4 2 1 32 46 39
3 3 1 36 50 58
4 2 2 40 50 51
2 2 Converted to standard care
3 3 0 43 60 57
5 3 2 38 59 59
2 2 2 28 45 62
2 2 1 30 52 57
4 3 0 27 48 69
5 4 2 37 62 48
5 4 0 34 53 44
6  1.2 2.7  0.8 35  6 53  6.1 55  9
2-5 2-4 27-45 45-62 39-69
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Dpolytetrafluoroethylene neochord from the leaflet. If MR was effectively
reduced under light tension of the suture, the neochordal position was
considered to be good and the neochord left in mitral valve leaflet
(Table 1 shows how many neochords were left in place after procedure).
In addition, a short-axis view was used to visualize the deployed neochords
to determine desired position on the P1, P2, or P3 scallop. Deployed
neochords were anchored to the epicardium by passing the sutures back
through the LV wall and then suturing to the epicardium over a pledget
adjacent to the ventriculotomy with a standard surgical knot. Tension
and securing of neochords was controlled by TEE to achieve maximal
competence of the mitral valve.
All patients have completed study follow-up visits before discharge and
at 30 days and 6 months after the procedure, with 1- and 2-year follow-up
ongoing.RESULTS
Acute procedure success was achieved in 92% of the
patients (12/13). Intraoperatively, 11 patients had less than
trivial MR (84%) and 2 patients had 1þ MR (16%). Our
first patient was converted to conventional mitral valve
repair due to failure to effectively deploy neochords.
Intraoperative conversion to standard open mitral valve
repair was successfully completed in this patient. Leaflet
damage could be seen during conventional mitral valve
repair. In this case, we can only speculate that fragile leaflet
tissue contributed to the inability to retain deployed
neochords. One patient with 2 neochords implanted has
developed recurrent MR at 30 day follow-up. In this patient
prolapsing segment was narrow, recurrence of MR in
this patient has developed due to dehiscence of 1 of the 2
deployed neochords.
Eleven remaining patients at 6 months’ follow-up had
MR of 2þ or less. Three patients (23% of all patients
with attempted treatment) had MR grade 0, 4 patients
(31%) had MR of grade 1, and the other 4 patients (31%)
had MR of grade 2 at the 6-month follow-up time point.
MR of 2þ or less was acceptable per protocol, and no
neochordal dehiscence was observed in these patients. Of
the 12 patients who had intraoperative success, 6 (50%)
had 2 neochords implanted, 4 (33%) had 3 neochords
implanted, and 2 (17%) had 4 neochords implanted.
At 6 months of follow-up, as would be expected, signs of
LV and left atrial reverse remodeling were observed
(Figure 2). Average LVend-diastolic diameter was reduced
from 57.6 mm preoperatively to 53.2 mm postoperatively
(reduction of 6%, P ¼ .002). Average LV end-systolic
diameter was slightly but nonsignificantly increased
from 35.2 to 35.5 mm (increase of 1%, P ¼ .86). Average
indexed left atrial volume was reduced from 69 to
55 mL/m2 (reduction of 20%, P ¼ .0004). Intraoperative
and postoperative patient data are listed in Table 1.
Average NeoChord procedure duration time was 113
minutes (range, 80-150 minutes). Typical neochord deploy-
ment time was less than 5 minutes per chord, with
tensioning and anchoring requiring about 10 minutes per
chord.98 The Journal of Thoracic and Cardiovascular SurgeOther than the conversion to standard care, there were no
major adverse events related to the transapical implantation
of neochords, and there were no other clinical events
or complications noted through the 6-month follow-up
period.
DISCUSSION
Transapical beating-heart implantation of neochords is a
novel surgical procedure for performing mitral valve repair
in patients with severe MR. The goal of the procedure is to
decrease the invasiveness of mitral valve repair procedures
and to avoid the risks of cardiopulmonary bypass and aortic
crossclamping.
The procedure of transapical implantation of neochords
has evolved during the TACT study. One of the procedural
refinements was to move the LV access and neochordal
anchoring site 2 to 4 cm posterolateral from the apex.
This difference from initial recommendations9 is based on
recent publications10 suggesting that the load on neochords
can be reduced by deploying shorter neochords with an
anchoring vector similar to that of native chordae. Also,
after late recurrence of MR in 1 of our patients, we focused
on deploying more neochords to reinforce mitral valve
competence. The TACT study does include early patients
(in other study sites) who have maintained a 1þ or trace
MR grade beyond 2 years with neochords anchored to the
LV apex; however, our early experience suggests that the
posterolateral access and anchoring site and the deployment
of multiple neochords together improve patient outcomes.
Selection of patient remains very important. One of our
patients with a narrow prolapsing segment had early
recurrence of MR, and we therefore believe that cases of
narrow prolapse are more challenging and should wait
more experience with the device.
In our patient group, transapical neochord implantation
under beating-heart conditions was feasible, could be
performed safely, and resulted in a relatively short proce-
dure time. Additional questions remain regarding this
promising repair technique. The long-term durability of
the NeoChord procedure remains to be proved. The target
population and pathology for use of this device has to be
found. Is it going to be patients who are described as ‘‘too
healthy’’ for conventional procedures or patients described
as ‘‘too sick’’ for surgery? Or both?
We are encouraged by our results in treating low-risk
patients with severe MR who are in need of a surgical
intervention. A more pressing clinical need is the treatment
of patients with a higher surgical risk profile. A beating-
heart off-pump procedure may offer a less-invasive
approach for treating patients for whom surgical treatment
is complicated by multiple comorbidities. With the conclu-
sion of the TACT Study and CE Mark, the TACT Registry
(clinicaltrials.gov ID: NCT01784055) has been initiated
in Europe. With more and different patients, the TACTry c January 2014
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Dregistry will help to clarify the surgical applications and
long-term results of this procedure.
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DrGeorg Lutter (Kiel, Germany). Congratulations on your lat-
est result. I want to ask you whether you measured the length of
your neochords between your apex and your posterior leaflet.
Did you put it more toward the posterolateral side, meaning that
this is more stable than seen in the patients in whom you put
your neochords directly towards the apex, and therefore did you
measure the length over time between the apex and the posterior
leaflet? We would like to know how to get stable results referring
to your neochords. What did you observe in your successful cases
with your repair of your posterior leaflet?
Dr Speziali. Proper tensioning of the neochords is a critical
element of this procedure, and intraoperatively we fill the heart
and we tension the neochords under direct visualization. We
pull the neochords enough to make the prolapse go away. ThereThe Journal of Thoracic and Cis a difference between the apex and the posterolateral segment
of the LV regarding the distance with the mitral annular plane:
the apex distance to the mitral plane is fixed, but the posterolat-
eral segment moves in and out during diastole and systole, and I
think that also reduces the snap on the neochords when the valve
closes. So it is not just a matter of length, it is a matter of force
applied to the chord that gets transmitted to the chord-leaflet
interface.
It is difficult to figure out in a few patients exactly what the
major determinant of neochordal tension and durability is, also
from an engineering and geometric standpoint.
Dr Lutter. Could you also imagine going with your NeoChord
device into one of the papillary muscles and then afterward going
into your posterior leaflet, P2, and fixing it over there?
Dr Speziali. I don’t want to stick that instrument through the
papillary muscle, because it is a lot of muscle you’d have to go
through. Possibly when we come out of the apex, however, we
can go back with a French eye needle and then reach the head of
the papillary muscle and then out again. It has been done in a
few of these cases.
Dr Thierry Mesana (Ottawa, Ontario, Canada). Congratula-
tions. This is a very nice device. I have 2 technical questions.
Maybe one you can answer; the other one you have to wait a
few years to answer.
First, can you really address P1 or P3 and not only P2? Most of
these posterior leaflet prolapses, or maybe half of them, are not
simple P2 prolapse. Second, do you think that by having your
device positioned in the apex and having to go through a thoraco-
tomy, you can induce adhesions and transformation of the apex and
then gradually with time have some fibrotic formation here? They
are going to change the anatomy of the chord itself implanted in
the apex. But it’s a nice study.
Dr Speziali. For the second question, we put a purse-string
suture with pledgets as for a transcatheter aortic valve implan-
tation, and that has not been a problem so far. The sutures
are actually anchored to the pledgets, not to the muscle itself.
So I think it’s unlikely that the pledget migrates or that changes
the geometry.
What was the first question?
Dr Williams. Whether you can treat P1 or P3, anterior leaflet.
Dr Speziali. The inclusion criteria didn’t specify P2.
Dr Williams. Do you think you can with this device? Do you
think you can treat P1 and P3?
Dr Speziali. Yes, I meant that we have done this. Both P1 and
P3 were treated in this series.ardiovascular Surgery c Volume 147, Number 1 99
